# **WEST Search History**

Hide Items Restore Clear Cancel

DATE: Wednesday, May 26, 2004

Hide?	Set Name	Query	Hit Count
	DB = USPT	T; PLUR=YES; OP=AND	
	L1	5688501.pn.	1
	DB=EPAE	3,JPAB,DWPI; PLUR=YE	S; OP=AND
The state of the s	L2	0414304 or 0403292	13
	DB=EPAE	B; PLUR=YES; OP=AND	
	L3	0414304	0
	DB=DWP	I; PLUR=YES; OP=AND	
	L4	0414304	3
	L5	414304	5
	L6	414304	5
	L7	403292	3

END OF SEARCH HISTORY

# **WEST Search History**

Hide Items Res	tore Clear	Cancel
----------------	------------	--------

DATE: Wednesday, May 26, 2004

Hide?	<u>Set</u> Name	Query	<u>Hit</u> Count
	DB=US	PT; PLUR=YES; OP=AND	
	L1	(\$phage or \$phages).clm.	2495
	L2	L1 and (method or process).clm.	2042
aproximal Average Control of the Con	L3	L2 and (treat\$ or therapeut\$ or prevent\$ or eradicat\$ or administer\$ or improv\$).clm.	808
	L4	host near3 range	5207
	L5	L4 and 11	252
	L6	15 and 12	195
20 de 10 de	L7	L6 and 13	63

END OF SEARCH HISTORY

Generate Collection

Print

## Search Results - Record(s) 1 through 50 of 63 returned.

1. <u>6699476</u> . 12 Jul 00; 02 Mar 04. Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules. Collins; Peter L., et al. 424/199.1; 424/202.1 424/205.1 424/211.1 435/69.1. A61K039/12 A61K039/295.
2. <u>6696295</u> . 28 Feb 01; 24 Feb 04. Transducing phages. Westpheling; Janet, et al. 435/472; 435/235.1 435/252.3 435/29 435/320.1 435/475 435/5 435/6 536/23.1. C12N015/09 C12N015/74 C12N007/00 C12Q001/68 C07H021/04.
3. 6656463. 08 Nov 01; 02 Dec 03. Compositions and methods for reducing the amount of salmonella in livestock. Harris; Delbert L., et al. 424/93.6; 424/93.3 435/235.1 435/239. A01N063/00.
4. 6635238. 14 Sep 01; 21 Oct 03. Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases. Delisle; Allan L 424/49; 424/50. A61K007/16.
5. <u>6589732</u> . 28 Feb 01; 08 Jul 03. Transducing phages. Westpheling; Janet, et al. 435/5; 435/235.1 435/252.1 435/29 435/472 435/475 435/6. C12Q001/70 C12Q001/68 C12Q001/02 C12N001/12 C12N001/20.
☐ 6. <u>6583121</u> . 12 Nov 99; 24 Jun 03. System for the in vivo delivery and expression of heterologous genes in the bone marrow. Johnston; Robert E., et al. 514/44; 435/320.1. A61K048/00 C12N015/64.
7. <u>6573090</u> . 09 Dec 99; 03 Jun 03. Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors. Breakefield; Xandra O., et al. 435/320.1; 424/199.1 424/201.1 424/202.1 424/203.1 424/229.1 424/234.1 424/93.1 435/235.1 435/239 435/456 435/6 435/69.1 514/44 536/23.1. C12N015/81 C12N015/70 C12N015/33 C12N015/38 C12N015/869.
8. <u>6528311</u> . 01 Mar 00; 04 Mar 03. Evolution of whole cells and organisms by recursive sequence recombination. delCardayre; Stephen, et al. 435/440; 435/6 536/23.1 536/24.3. C12N015/00 C12Q001/68 C07H021/02 C07H021/04.
9. <u>6497882</u> . 07 Jun 95; 24 Dec 02. Recombinant swinepox virus. Cochran; Mark D., et al. 424/199.1; 424/93.2 435/235.1 435/320.1. A61K039/12 A61K039/275 C12N007/01 C12N015/863.
10. <u>6495318</u> . 24 Dec 98; 17 Dec 02. Method and kits for preparing multicomponent nucleic acid constructs. Harney; Peter D 435/6; 435/254.2 435/320.1 435/91.1 435/91.2 536/22.1 536/24.3 536/24.3 536/24.5. C12Q001/68 C07H019/00 C07H021/00 C07H021/02.
☐ 11. <u>6485902</u> . 05 Jun 01; 26 Nov 02. Use of bacteriophages for control of escherichia coli O157. Waddell; Thomas E., et al. 435/5; 424/93.6. C12Q001/70 A01N063/00.
12. <u>6482635</u> . 28 Sep 01; 19 Nov 02. Method of reducing off-flavor in water or aquatic life forms using Bacterium NRRL B-30043. Walker; Harrell L., et al. 435/243; 435/257.1 435/822. C12N001/00 C12N001/12 C12N001/20.
☐ 13. <u>6482632</u> . 21 Apr 99; 19 Nov 02. Bacteriophage, a process for the isolation thereof, and a

```
SYSTEM:OS - DIALOG OneSearch
 File 155:MEDLINE(R) 1966-2004/May W3
         (c) format only 2004 The Dialog Corp.
*File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.
 File 73:EMBASE 1974-2004/May W3
         (c) 2004 Elsevier Science B.V.
 File 286:Biocommerce Abs. & Dir. 1981-2004/Apr B2
         (c) 2004 BioCommerce Data Ltd.
  File 440:Current Contents Search(R) 1990-2004/May 26
         (c) 2004 Inst for Sci Info
  File 340:CLAIMS(R)/US Patent 1950-04/May 20
         (c) 2004 IFI/CLAIMS(R)
*File 340: Annual reload and classification updates delayed due
 to Dialog processing issues.
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
 File
         5:Biosis Previews(R) 1969-2004/May W3
         (c) 2004 BIOSIS
  File 399:CA SEARCH(R) 1967-2004/UD=14022
         (c) 2004 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
  File 144:Pascal 1973-2004/May W3
         (c) 2004 INIST/CNRS
  File 348:EUROPEAN PATENTS 1978-2004/May W03
         (c) 2004 European Patent Office
         9:Business & Industry(R) Jul/1994-2004/May 25
  File
         (c) 2004 The Gale Group
  File 34:SciSearch(R) Cited Ref Sci 1990-2004/May W3
         (c) 2004 Inst for Sci Info
  File 128:PHARMAPROJECTS 1980-2004/May W2
         (c) 2004 PJB Publications, Ltd.
  File 319: Chem Bus NewsBase 1984-2004/May 26
         (c) 2004 Elsevier Eng. Info. Inc.
*File 319: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.
  File 342:Derwent Patents Citation Indx 1978-04/200428
         (c) 2004 Thomson Derwent
  File 349:PCT FULLTEXT 1979-2002/UB=20040520,UT=20040513
         (c) 2004 WIPO/Univentio
  File 50:CAB Abstracts 1972-2004/Apr
         (c) 2004 CAB International
  File 107:Adis R&D Insight 1986-2004/May W3
         (c) 2004 Adis Data Information BV.
  File 345:Inpadoc/Fam.& Legal Stat 1968-2004/UD=200419
         (c) 2004 EPO
*File 345: October 12, 2003 - changes to legal status now online.
See HELP NEWS 345 for details.
  File 357: Derwent Biotech Res. 1982-2004/May W4
         (c) 2004 Thomson Derwent & ISI
  File 16:Gale Group PROMT(R) 1990-2004/May 26
         (c) 2004 The Gale Group
*File 16: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.
  File 35:Dissertation Abs Online 1861-2004/Apr
         (c) 2004 ProQuest Info&Learning
  File 71:ELSEVIER BIOBASE 1994-2004/May W3
         (c) 2004 Elsevier Science B.V.
  File 98:General Sci Abs/Full-Text 1984-2004/May
         (c) 2004 The HW Wilson Co.
  File 143:Biol. & Agric. Index 1983-2004/Apr
         (c) 2004 The HW Wilson Co
```

Set Items Description
S1 103 BACTERIOPHAG?/TI (100N) THERAPEUT?
S2 76 RD (unique items)
?t s2/3,kwic/52
>>>KWIC option is not available in file(s): 399

2/3,KWIC/52 (Item 2 from file: 348)

(c) 2004 European Patent Office. All rts. reserv.

DIALOG(R) File 348: EUROPEAN PATENTS

01504737

METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES

PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES
THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET
PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES
PATENT ASSIGNEE:

Biophage, Inc., (3936210), 6100 Royalmount, Montreal, Quebec H4P 2R2, (CA), (Applicant designated States: all)

INVENTOR:

MANDEVILLE, Rosemonde, 781 Thibault, Ste-Therese, Quebec J7E 4B9, (CA) ALLAIN, Beatrice, 8434 St-Hubert, Montreal, Quebec H2P 1Z5, (CA) MURTHY, Kishore, 24 Linton, Dollard des Ormeaux, Quebec H9B 1P3, (CA) PATENT (CC, No, Kind, Date):

WO 2002086154 021031

APPLICATION (CC, No, Date): EP 2002764031 020419; WO 2002CA569 020419 PRIORITY (CC, No, Date): US 284517 P 010419 DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI;

LU; MC; NL; PT; SE; TR

EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

INTERNATIONAL PATENT CLASS: C12Q-001/68

LANGUAGE (Publication, Procedural, Application): English; English; English

- METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES
- PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES
  THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET
  PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES
  ?logoff hold

26may04 08:41:21 User228206 Session D2178.5

Description .Set Items BACTERIOPHAG?/TI (100N) THERAPEUT? 103 S1 S2 76 RD (unique items) ?t s2/3,kwic/52 >>>KWIC option is not available in file(s): 399 (Item 2 from file: 348) 2/3,KWIC/52 DIALOG(R) File 348: EUROPEAN PATENTS (c) 2004 European Patent Office. All rts. reserv. 01524737 METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES PATENT ASSIGNEE: Biophage, Inc., (3936210), 6100 Royalmount, Montreal, Quebec H4P 2R2, (CA), (Applicant designated States: all) INVENTOR: MANDEVILLE, Rosemonde, 781 Thibault, Ste-Therese, Quebec J7E 4B9, (CA) ALLAIN, Beatrice, 8434 St-Hubert, Montreal, Quebec H2P 1Z5, (CA) MURTHY, Kishore, 24 Linton, Dollard des Ormeaux, Quebec H9B 1P3, (CA) PATENT (CC, No, Kind, Date): WO 2002086154 021031 EP 2002764031 020419; WO 2002CA569 020419 APPLICATION (CC, No, Date): PRIORITY (CC, No, Date): US 284517 P 010419 DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI INTERNATIONAL PATENT CLASS: C12Q-001/68 LANGUAGE (Publication, Procedural, Application): English; English; English

- METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES
- PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES
  THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET
  PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES
  ?logoff hold
  - 26may04 08:41:21 User228206 Session D2178.5

#### First Hit Fwd Refs

L7: Entry 1 of 63

File: USPT

Mar 2, 2004

US-PAT-NO: 6699476

DOCUMENT-IDENTIFIER: US 6699476 B1

TITLE: Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules

DATE-ISSUED: March 2, 2004

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE COUNT	rry
Collins; Peter L.	Rockville	MD	20852	
Bukreyev; Alexander	Rockville	MD	20851	
Murphy; Brian P.	Bethesda	MD	20816	
Whitehead; Stephen S.	Gaithersburg	MD	20878	

APPL-NO: 09/ 614285 [PALM] DATE FILED: July 12, 2000

#### PARENT-CASE:

CROSS-REFERENCES TO RELATED APPLICATIONS This application claims the priority benefit of U.S. Provisional Application No. 60/143,425, filed by Peter L. Collins et al. on Jul. 13, 1999. The present application also claims the benefit of and is a continuation-in-part of U.S. patent application Ser. No. 09/291,894, filed Apr. 13, 1999, which is a continuation-in-part of U.S. patent application Ser. No. 08/892,403, filed Jul. 15, 1997, issued on Nov. 30, 1999 as U.S. Pat. No. 5,993,824, which is entitled to priority from U.S. Provisional Application Nos. 60/047,634, filed May 23, 1997; 60/046,141, filed May 9, 1997; and 60/021,773, filed Jul. 15, 1996, each of which is incorporated herein by reference.

INT-CL: [07] A61 K 39/12, A61 K 39/295

US-CL-ISSUED: 424/199.1; 424/202.1, 424/205.1, 424/211.1, 435/69.1 US-CL-CURRENT: 424/199.1; 424/202.1, 424/205.1, 424/211.1, 435/69.1

FIELD-OF-SEARCH: 424/85.1, 424/85.2, 424/85.4, 424/85.5, 424/85.6, 424/85.7, 424/184.1, 424/199.1, 424/205.1, 424/211.1, 435/69.1

PRIOR-ART-DISCLOSED:

### U.S. PATENT DOCUMENTS

	Search Selected ,	Search ALL Clear	
PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5716821	February 1998	Wertz et al.	435/235.1
5789229	August 1998	Wertz et al.	435/235.1

```
*** DIALINDEX search results display in an abbreviated ***
*** format unless you enter the SET DETAIL ON command. ***
?sf allscience
   You have 283 files in your file list.
   (To see banners, use SHOW FILES command)
### Status: Break Sent.
?s bacteriophag?/ti (100n) therapeut?
Your SELECT statement is:
   s bacteriophag?/ti (100n) therapeut?
                  File
           Items
                    5: Biosis Previews(R)_1969-2004/May W3
                    9: Business & Industry(R)_Jul/1994-2004/May 25
               3
                    16: Gale Group PROMT(R)_1990-2004/May 26
               1
                   34: SciSearch(R) Cited Ref Sci_1990-2004/May W3
                    35: Dissertation Abs Online_1861-2004/Apr
               1
                    50: CAB Abstracts 1972-2004/Apr
                    71: ELSEVIER BIOBASE_1994-2004/May W3
              10
                    73: EMBASE 1974-2004/May W3
                    98: General Sci Abs/Full-Text_1984-2004/May
               1
       Examined 50 files
>>>Term "TI" is not defined in file 107 and is ignored
                  107: Adis R&D Insight_1986-2004/May W3
               2
>>>Term "TI" is not defined in file 128 and is ignored
               3 128: PHARMAPROJECTS_1980-2004/May W2
               1
                   143: Biol. & Agric. Index_1983-2004/Apr
                   144: Pascal 1973-2004/May W3
               4
                   148: Gale Group Trade & Industry DB 1976-2004/May 26
               1
                   149: TGG Health&Wellness DB(SM)_1976-2004/May W3
               1
                  155: MEDLINE(R) 1966-2004/May W3
       Examined 100 files
                  285: BioBusiness(R)_1985-1998/Aug W1
               1
>>>Term "TI" is not defined in file 286 and is ignored
                   286: Biocommerce Abs.& Dir._1981-2004/Apr B2
              10
                   315: ChemEng & Biotec Abs 1970-2004/Apr
                   319: Chem Bus NewsBase_1984-2004/May 26
                   331: Derwent WPI First View
                                                   UD=200432
                   340: CLAIMS(R)/US Patent 1950-04/May 20
                   342: Derwent Patents Citation Indx 1978-04/200428
                   345: Inpadoc/Fam. & Legal Stat 1968-2004/UD=200419
       Examined 150 files
                   348: EUROPEAN PATENTS 1978-2004/May W03
                    349: PCT FULLTEXT 1979-2002/UB=20040520, UT=20040513
                   357: Derwent Biotech Res. 1982-2004/May W4 358: Current BioTech Abs 1983-2004/Apr
                   399: CA SEARCH(R)_1967-2004/UD=14022
434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
                   440: Current Contents Search(R) 1990-2004/May 26
       Examined 200 files
                   636: Gale Group Newsletter DB(TM) 1987-2004/May 26
                    654: US Pat.Full. 1976-2004/May 18
       Examined 250 files
   33 files have one or more items; file list includes 283 files.
   One or more terms were invalid in 94 files.
?save temp
Temp SearchSave "TD823" stored
Your last SELECT statement was:
   S BACTERIOPHAG?/TI (100N) THERAPEUT?
                   File
Ref
           Items
           ----
N1
              14
                   155: MEDLINE(R) 1966-2004/May W3
```

```
73: EMBASE 1974-2004/May W3
              10
N2
              10* 286: Biocommerce Abs.& Dir. 1981-2004/Apr B2
N3
                   440: Current Contents Search (R) 1990-2004/May 26
N4
              8
N5
                   340: CLAIMS(R)/US Patent_1950-04/May 20
                   434: SciSearch(R) Cited Ref Sci_1974-1989/Dec
N6
                     5: Biosis Previews(R)_1969-2004/May W3
N7
               5
                   399: CA SEARCH(R)_1967-2004/UD=14022
               5
Ν8
                   144: Pascal 1973-2004/May W3
Ν9
                   348: EUROPEAN PATENTS_1978-2004/May W03
N10
   33 files have one or more items; file list includes 283 files.
   * One or more search terms are invalid in this file
        - Enter P or PAGE for more -
?b n1:n25;exs
       26may04 08:19:52 User228206 Session D2178.2
            $5.59 2.485 DialUnits File411
     $5.59 Estimated cost File411
     $0.50 TELNET
     $6.09 Estimated cost this search
     $6.11 Estimated total session cost 2.645 DialUnits
SYSTEM:OS - DIALOG OneSearch
  File 155:MEDLINE(R) 1966-2004/May W3
         (c) format only 2004 The Dialog Corp.
*File 155: Medline has been reloaded. Accession numbers
have changed. Please see HELP NEWS 154 for details.
  File 73:EMBASE 1974-2004/May W3
         (c) 2004 Elsevier Science B.V.
  File 286:Biocommerce Abs. & Dir. 1981-2004/Apr B2
         (c) 2004 BioCommerce Data Ltd.
  File 440:Current Contents Search(R) 1990-2004/May 26
         (c) 2004 Inst for Sci Info
  File 340:CLAIMS(R)/US Patent 1950-04/May 20
         (c) 2004 IFI/CLAIMS(R)
*File 340: Annual reload and classification updates delayed due
 to Dialog processing issues.
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 1998 Inst for Sci Info
  File
         5:Biosis Previews(R) 1969-2004/May W3
         (c) 2004 BIOSIS
  File 399:CA SEARCH(R) 1967-2004/UD=14022
         (c) 2004 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
Alert feature enhanced for multiple files, etc. See HELP ALERT.
  File 144: Pascal 1973-2004/May W3
         (c) 2004 INIST/CNRS
  File 348: EUROPEAN PATENTS 1978-2004/May W03
         (c) 2004 European Patent Office
  File
         9:Business & Industry(R) Jul/1994-2004/May 25
         (c) 2004 The Gale Group
        34:SciSearch(R) Cited Ref Sci 1990-2004/May W3
         (c) 2004 Inst for Sci Info
  File 128:PHARMAPROJECTS 1980-2004/May W2
         (c) 2004 PJB Publications, Ltd.
  File 319: Chem Bus NewsBase 1984-2004/May 26
         (c) 2004 Elsevier Eng. Info. Inc.
*File 319: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.
  File 342:Derwent Patents Citation Indx 1978-04/200428
         (c) 2004 Thomson Derwent
  File 349:PCT FULLTEXT 1979-2002/UB=20040520,UT=20040513
         (c) 2004 WIPO/Univentio
  File 50:CAB Abstracts 1972-2004/Apr
         (c) 2004 CAB International
  File 107:Adis R&D Insight 1986-2004/May W3
         (c) 2004 Adis Data Information BV.
  File 345:Inpadoc/Fam.& Legal Stat 1968-2004/UD=200419
         (c) 2004 EPO
```

```
*File 345: October 12, 2003 - changes to legal status now online.
See HELP NEWS 345 for details.
  File 357:Derwent Biotech Res. 1982-2004/May W4
         (c) 2004 Thomson Derwent & ISI
       16:Gale Group PROMT(R) 1990-2004/May 26
         (c) 2004 The Gale Group
*File 16: Alert feature enhanced for multiple files, duplicate
removal, customized scheduling. See HELP ALERT.
  File 35:Dissertation Abs Online 1861-2004/Apr
         (c) 2004 ProQuest Info&Learning
       71:ELSEVIER BIOBASE 1994-2004/May W3
  File
         (c) 2004 Elsevier Science B.V.
  File 98:General Sci Abs/Full-Text 1984-2004/May
         (c) 2004 The HW Wilson Co.
  File 143:Biol. & Agric. Index 1983-2004/Apr
         (c) 2004 The HW Wilson Co
      Set Items Description
      ___ _____
Executing TD823
>>>SET HILIGHT: use ON, OFF, or 1-5 characters
>>>Term "TI" is not defined in one or more files
           74807 BACTERIOPHAG?/TI
         3281222 THERAPEUT?
             103 BACTERIOPHAG?/TI (100N) THERAPEUT?
      S1
?rd
>>>Duplicate detection is not supported for File 286.
>>>Duplicate detection is not supported for File 340.
>>>Duplicate detection is not supported for File 348.
>>>Duplicate detection is not supported for File 128.
>>>Duplicate detection is not supported for File 342.
>>>Duplicate detection is not supported for File 349.
>>>Duplicate detection is not supported for File 107.
>>>Duplicate detection is not supported for File 345.
>>>Records from unsupported files will be retained in the RD set.
>>>Record 440:16267483 ignored; incomplete bibliographic data, not retained
 in RD set
>>>Record 440:13230268 ignored; incomplete bibliographic data, not retained
>>>Record 440:11184716 ignored; incomplete bibliographic data, not retained
 in RD set
>>>Record 440:7307911 ignored; incomplete bibliographic data, not retained
in RD set
>>>Record 440:3917940 ignored; incomplete bibliographic data, not retained
in RD set
...examined 50 records (50)
...examined 50 records (100)
...completed examining records
      S2
              76 RD (unique items)
?t s2/6,kwic/all
>>>KWIC option is not available in file(s): 399
                (Item 1 from file: 155)
 2/6,KWIC/1
DIALOG(R) File 155:(c) format only 2004 The Dialog Corp. All rts. reserv.
           PMID: 14565130
16046689
   Mode of the rational use of Pseudomonas aeruginosa bacteriophages
 therapeutic and epidemic control practice]
  Puti ratsional'nogo ispol'zovaniia sinegnoinykh bakteriofagov v lechebnoi
i protivoepidemicheskoi praktike.
Sep-Oct 2003
   Mode of the rational use of Pseudomonas aeruginosa bacteriophages in
 therapeutic and epidemic control practice]
```

(Item 2 from file: 155)

DIALOG(R) File 155:(c) format only 2004 The Dialog Corp. All rts. reserv.

2/6,KWIC/2

```
Cost is in DialUnits
        Items
                Description
Set
                BACTERIOPHAG?/TI (100N) THERAPEUT?
          103
          76
                RD (unique items)
?t s2/9/4 5 6 7 8 9 10-12 13 14 16 19 69
           (Item 4 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
09413900
           PMID: 1380753
                                     and
                                            therapeutic
                                                            effectiveness of
    Immunobiological properties
preparations from Klebsiella bacteriophages ]
                                    i terapevticheskaia
                                                                effektivnost'
  Immunobiologicheskie svoistva
preparatov bakteriofagov klebsiell.
  Bogovazova G G; Voroshilova N N; Bondarenko V M; Gorbatkova G A;
Afanas'eva E V; Kazakova T B; Smirnov V D; Mamleeva A G; Glukharev Iu A;
Erastova E I; et al
  Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR)
    (3) p30-3, ISSN 0372-9311 Journal Code: 0415217
  Document type: Journal Article ; English Abstract
  Languages: RUSSIAN
  Main Citation Owner: NLM
  Record type: Completed
            INDEX MEDICUS
  Subfile:
                  preparations of Klebsiella bacteriophages, viz. the
        purified
  The
monovalent preparation of K. pneumoniae bacteriophage and the polyvalent
bacteriophage preparation for the treatment of infections caused by K.
ozaenae, K. rhinoscleromatis scleromatis and K. pneumoniae sensu lato, have
been obtained. The bacteriophage preparations have proved to be nontoxic
and safe for laboratory animals after the intraperitoneal injection of
these preparations followed by the pathomorphological study of the internal
organs of the animals. The clinical study of the newly developed bacteriophage preparations in the course of the treatment of purulent inflammatory diseases in 109 patients has revealed that the preparations
are not reactogenic and exhibit sufficient effectiveness in the therapy of
ozena, rhinoscleroma and Klebsiella infections with different localization
of the infectious process.
  Tags: Human
                                                    *Klebsiella
  Descriptors:
                 *Bacteriophages;
                                    *Klebsiella;
                Animals; Bacteriophages--immunology--IM; Chromatography,
--therapy--TH;
Liquid; Klebsiella--immunology--IM; Mice; O Antigens; Polysaccharides,
Bacterial -- isolation and purification -- IP
  CAS Registry No.: 0 (O Antigens); 0
                                          (Polysaccharides, Bacterial)
  Record Date Created: 19920923
  Record Date Completed: 19920923
 2/9/5
           (Item 5 from file: 155)
DIALOG(R) File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
           PMID: 2796659
   Bacteriophages and their therapeutic -prophylactic use]
  Bakteriofagi i ikh lechebno-profilakticheskoe primenenie.
  Chernomordik A B
  Meditsinskaia sestra (USSR)
                                 Jun 1989, 48 (6) p44-7, ISSN 0025-8342
Journal Code: 18620490R
  Document type: Journal Article
  Languages: RUSSIAN
  Main Citation Owner: NLM
  Record type: Completed
             NURSING
  Subfile:
  Tags: Human
  Descriptors: *Bacteriophages; *Biological Factors--therapeutic use--TU;
Bacterial Infections -- prevention and control -- PC; Bacterial Infections
--therapy--TH
```

CAS Registry No.: 0 (Biological Factors)

Record Date Created: 19891122 Record Date Completed: 19891122

### 2/9/6 (Item 6 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07687545 PMID: 3124795

Investigation on the therapeutical efficiency of some adapted bacteriophages in experimental infection with Pseudomonas aeruginosa.

Meitert E; Petrovici M; Sima F; Costache G; Savulian C

Archives roumaines de pathologie experimentales et de microbiologie (ROMANIA) Jan-Mar 1987, 46 (1) p17-26, ISSN 0004-0037 Journal Code: 0421056

Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS
Tags: Comparative Study

Descriptors: \*Bacteriophages; \*Biological Products--therapeutic use--TU; \*Pseudomonas Infections--therapy--TH; Animals; Burns--complications--CO; Burns--mortality--MO; Burns--therapy--TH; Evaluation Studies; Mice; Pneumonia--mortality--MO; Pneumonia--therapy--TH; Pseudomonas Infections--mortality--MO; Pseudomonas aeruginosa; Septicemia--mortality--MO;

Septicemia--therapy--TH; Time Factors

CAS Registry No.: 0 (Biological Products)

Record Date Created: 19880229
Record Date Completed: 19880229

#### 2/9/7 (Item 7 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

05715128 PMID: 7304029

Experience in the therapeutic use of bacteriophage preparations in suppurative surgical infections]

Opyt lechebnogo primeneniia preparatov bakteriofaga pri gnoino-khirurgicheskikh infektsiiakh.

Peremitina L D; Berillo E A; Khvoles A G

Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR) Sep 1981,

(9) p109-10, ISSN 0372-9311 Journal Code: 0415217

Document type: Journal Article

Languages: RUSSIAN
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS

Tags: Human

Descriptors: \*Bacteriophages; \*Surgical Wound Infection--therapy--TH

Record Date Created: 19820120 Record Date Completed: 19820120

#### 2/9/8 (Item 8 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

04953788 PMID: 734488

Therapeutic effect of bacteriophage preparations in the complex treatment of suppurative surgical diseases]

Izuchenie terapevticheskogo effekta preparatov bakteriofaga v kompleksnom lechenii gnoinykh khirurgicheskikh zabolevanii.

Zhukov-Verezhnikov N N; Peremitina L D; Berillo E A; Komissarov V P; Bardymov V M

Sovetskaia meditsina (USSR) Dec 1978, (12) p64-6, ISSN 0038-5077

Journal Code: 0404525

Document type: Journal Article ; English Abstract

Languages: RUSSIAN
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS

Tags: Human

Descriptors: \*Bacteriophages; \*Infection--therapy--TH; \*Surgical Wound Infection--therapy--TH; Staphylococcal Infections--therapy--TH; Suppuration

Record Date Created: 19790324
Record Date Completed: 19790324

## 2/9/9 (Item 9 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

04187503 PMID: 128959

Sensitivity to polyvalent therapeutic staphylococcal bacteriophage as a supplementary criterion of staphylococcal pathogenicity]

Chuvstvitel'nost' k polivalentnomu lechebnmu stafilokokkovomu bakteriofagu kak dopolnitel'nyi kriterii patogennosti stafilokokkov Fel'dman Iu M; Liubchich L S; Chudner V Z; Usachev G I; Shtefanek L A Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR) Oct 1975,

(10) p59-60, ISSN 0372-9311 Journal Code: 0415217 Document type: Journal Article; English Abstract

Languages: RUSSIAN

Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

It is recommended to use the capacity of pathogenic staphylococci to be lysed by polyvalent therapeutic staphylococcal bacteriophage in the capacity of an additional simple and accessible criterion of staphylococcus pathogenicity. Of 147 strains of the pathogenic plasmacoagulating staphylococci 101 were lysed by the phage and of 166 nonplasmocoagulating nonpathogenic strains--only 6. This test correlated with the other signs of staphylococcus (lecithinase and hemolytic activity). The simplicity and sufficient specificity of this test permits to use it in any practical laboratory. Polyvalent diagnostic phage can be used on the basis of therapeutic bacteriophage by its additional adaptation to the pathogenic strains of staphylococcus.

Descriptors: \*Bacteriolysis; \*Staphylococcus--pathogenicity--PY; \*Staphylococcus Phages--physiology--PH; Bacteriological Techniques; Hemolysis; Phospholipases--metabolism--ME; Staphylococcus--enzymology--EN

Enzyme No.: EC 3.1.- (Phospholipases) Record Date Created: 19760330

Record Date Completed: 19760330

## 2/9/10 (Item 10 from file: 155)

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

03923514 PMID: 4439019

d'Herelle's bacteriophage and its' therapeutic property]
Le bacteriophage de d'Herelle et son pouvoir therapeutique

Raiga-Clemenceau A

Semaine des hopitaux. Therapeutique (FRANCE) Mar 1974, 50 (3) p229-31, ISSN 0040-5922 Journal Code: 0415603

Document type: Journal Article

Languages: FRENCH

Main Citation Owner: NLM Record type: Completed Subfile: INDEX MEDICUS

Descriptors: \*Bacterial Infections--therapy--TH; \*Bacteriophages;

Bacteriolysis--methods--MT Record Date Created: 19750310 Record Date Completed: 19750310

```
(Item 11 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
03425486
           PMID: 5071621
                                      therapeutic -prophylactic newcastle
   Biological characteristics of
bacteriophages manufactured by different institutes]
  Biologicheskie osobennosti lechebno-profilakticheskikh fagov M'iukasl
proizvodstva razlichnykh institutov.
 Voroshilova N N; Bobkova E V
  Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR)
                                                                   Jun 1972,
     (6) p47-50, ISSN 0372-9311 Journal Code: 0415217
 Document type: Journal Article
 Languages: RUSSIAN
 Main Citation Owner: NLM
 Record type: Completed
  Subfile: INDEX MEDICUS
 Descriptors:
                  *Bacteriophages;
                                      *Dysentery,
                                                    Bacillary--therapy--TH;
*Newcastle disease virus
 Record Date Created: 19721116
 Record Date Completed: 19721116
            (Item 12 from file: 155)
 2/9/12
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
03035826
          PMID: 4250167
   Use of staphylococcal bacteriophage for therapeutic and preventive
  Primenenie stafilokokkovogo bakteriofaga s lechebnoi i profilakteicheskoi
tsel'iu.
  Proskurov V A
  Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR) Feb 1970,
 47 (2) p104-7, ISSN 0372-9311 Journal Code: 0415217 Document type: Journal Article
 Languages: RUSSIAN
 Main Citation Owner: NLM
 Record type: Completed
 Subfile:
            INDEX MEDICUS
  Tags: Female; Human
                *Staphylococcal Infections -- therapy -- TH; *Staphylococcus
 Descriptors:
Phages; Adult; Staphylococcal Infections -- prevention and control -- PC
  Record Date Created: 19710227
 Record Date Completed: 19710227
 2/9/13
            (Item 13 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
02474640
          PMID: 4232630
   Efficacy of the combined use of
                                         therapeutic vaccine and specific
bacteriophage in experimental brucellosis]
  Effektivnost' kombinirovannogo primeneniia
                                                     lechenoi
spetsificheskogo bakteriofaga pri eksperimental'nom brutselleze.
  Popkhadze M Z; Abashidze T G; Karichashvili L N
 Zhurnal mikrobiologii, epidemiologii, i immunobiologii (USSR)
                                                                   Jan 1968,
 45 (1) p93-6, ISSN 0372-9311
Document type: Journal Article
                                    Journal Code: 0415217
 Languages: RUSSIAN
 Main Citation Owner: NLM
 Record type: Completed
 Subfile:
           INDEX MEDICUS
 Descriptors:
                 *Bacteriophages;
                                      *Brucellosis,
                                                       Bovine--therapy--TH;
*Immunotherapy; Animals; Cattle; Georgia (Republic); Guinea Pigs
 Record Date Created: 19680905
 Record Date Completed: 19680905
```

```
(Item 14 from file: 155)
 2/9/14
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2004 The Dialog Corp. All rts. reserv.
02265903
          PMID: 5877585
   Acute and chronic diarrhea in adults. Therapeutic importance of the
 bacteriophage ]
 Les diarrhees aigues et chroniques de l'adulte. Interet therapeutique
 du bacteriophage .
  Ligny G
  Semaine
            therapeutique (FRANCE)
                                     Oct 1963, 39
                                                      (8)
                                                            p499-505,
0040-5922
           Journal Code: 0205463
  Document type: Journal Article
  Languages: FRENCH
  Main Citation Owner: NLM
  Record type: Completed
  Subfile: INDEX MEDICUS
  Tags: Human
  Descriptors: *Anti-Bacterial Agents--therapeutic use--TU; *Bacteriophages
  *Celiac Disease--therapy--TH; *Colitis--therapy--TH; *Diarrhea--therapy
--TH; *Diverticulitis--therapy--TH
  CAS Registry No.: 0
                        (Anti-Bacterial Agents)
  Record Date Created: 19670903
  Record Date Completed: 19670903
 2/9/16
            (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.
            EMBASE No: 1979130034
01409260
 New trends in therapeutic use of bacteriophages
  DONNEES ACTUELLES SUR LES APPLICATIONS THERAPEUTIQUES DES
BACTERIOPHAGES
  Vieu J.F.; Guillermet F.; Minck R.; Nicolle P.
  Inst. Pasteur, 75015 Paris France
  Bulletin de l'Academie Nationale de Medecine (BULL. ACAD. NATL. MED. ) (
  France) 1979, 163/1 (61-66)
  CODEN: BANMA
  DOCUMENT TYPE: Journal
  LANGUAGE: FRENCH
                    SUMMARY LANGUAGE: ENGLISH
DRUG DESCRIPTORS:
*antibiotic agent
MEDICAL DESCRIPTORS:
*bacteriophage; *urinary tract infection
drug resistance; drug therapy; therapy
SECTION HEADINGS:
  037
      Drug Literature Index
  047
      Virology
      Microbiology: Bacteriology, Mycology, Parasitology and Virology
  004
  009
      Surgery
      Clinical and Experimental Pharmacology
 2/9/19
            (Item 5 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2004 Elsevier Science B.V. All rts. reserv.
00616021
             EMBASE No: 1976171668
  Sensitivity to polyvalent therapeutic staphylococcus bacteriophage as
an additional criterion of pathogenicity (Russian)
  Feldman Yu. M.; Lyubchich L.S.; Chudner V.Z.; et al.
  Sanit. Epidemiol. Stants., Zhitomir Russia
  Zhurnal Mikrobiologii Epidemiologii i Immunobiologii ( ZH. MIKROBIOL.
  EPIDEMIOL. IMMUNOBIOL. ) 1975, 52/10 (59-60)
  CODEN: ZMEIA
  DOCUMENT TYPE: Journal
  LANGUAGE: RUSSIAN
```

```
MEDICAL DESCRIPTORS:
*bacteriophage; *staphylococcus aureus
microorganism; in vitro study; theoretical study; methodology
SECTION HEADINGS:
  004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
 2/9/69
            (Item 1 from file: 50)
DIALOG(R) File 50:CAB Abstracts
(c) 2004 CAB International. All rts. reserv.
02249062
           CAB Accession Number: 902205897
                   efficacy of polyvalent staphylococcal bacteriophage in
     Therapeutic
bovine mastitis.
   Niyaz, N. M.
   Vsesoyuznyi Institut Eksper. Veterinarii, Moscow, USSR.
   Byulleten' Vsesoyuznogo Instituta Eksperimental'noi Veterinarii vol. 65
 p.80-81
   Publication Year: 1988 --
   Language: Russian
   Document Type: Journal article
   Four batches of Tiflis polyvalent bacteriophage, Gorki polyvalent phage
 and a phage isolated from sewage, tested against 280 cultures of mastitis
 staphylococci, lysed between 23 and 88% of cultures, the Gorki phage being
 most efficient. The last-named was infused into the udder of 30 cows with
 staphylococcal mastitis, using 50 ml for each quarter, once daily for 3
 days. 14 of them were bacteriologically negative after treatment.
 DESCRIPTORS: Bovine mastitis; therapy; Cows; Mastitis; microorganisms;
    bacterial diseases
 ORGANISM DESCRIPTORS: Staphylococcus aureus; bacteriophages;
    Staphylococcus
 BROADER TERMS: female animals; animals; Staphylococcus; Micrococcaceae;
    Firmicutes; bacteria; prokaryotes; viruses
 CABICODES: Parasites, Vectors, Pathogens & Biogenic Diseases of Animals
    (LL820)
?t s2/3,kwic/45 46 74 75
>>>KWIC option is not available in file(s): 399
 2/3,KWIC/45
                 (Item 1 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.
  140284034
               CA: 140(18)284034w
                                    DISSERTATION
  A tale of two viruses with therapeutic potential: structural studies on
CELO, an avian adenovirus, and the bacteriophage PRD1
  AUTHOR(S): Xu, Lan
  LOCATION: Univ. of Pennsylvania, Philadelphia, PA, USA
  DATE: 2002 PAGES: 234 pp. CODEN: DABBBA LANGUAGE: English CITATION:
Diss. Abstr. Int., B 2003, 63(11), 5230 AVAIL: UMI, Order No. DA3073076
 2/3,KWIC/46
                 (Item 2 from file: 399)
DIALOG(R) File 399:CA SEARCH(R)
(c) 2004 American Chemical Society. All rts. reserv.
  137347478
               CA: 137(24)347478e
                                    PATENT
  Methods for labeling and monitoring genetically modified bacteriophages
and generating therapeutic bacteriophage libraries with desired safety
characteristics
  INVENTOR (AUTHOR): Mandeville, Rosemonde; Allain, Beatrice; Murthy,
Kishore
  LOCATION: Can.,
  ASSIGNEE: Biophage, Inc.
  PATENT: PCT International; WO 200286154 A2 DATE: 20021031
  APPLICATION: WO 2002CA569 (20020419) *US PV284517 (20010419)
  PAGES: 41 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C120-001/68A
  DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
```

```
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG
```

# 2/3,KWIC/74 (Item 2 from file: 345) DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat (c) 2004 EPO. All rts. reserv.

### 16977069

Basic Patent (No, Kind, Date): US 5985271 A 19991116 <No. of Patents: 097>
Prophylactic and theraputic treatment of group A streptococcal infection
(English)

Patent Assignee: NEW HORIZONS DIAGNOSTICS CORP (US)

Author (Inventor): FISCHETTI VINCENT (US); LOOMIS LAWRENCE (US)

National Class: \*424094100; 424045000; 424440000; 424489000; 424464000;

514002000; 514937000; 514944000

IPC: \*A61K-038/43;

Derwent WPI Acc No: C 00-012759 Language of Document: English

Patent Family:

tent	Family:								
Pat	ent No	Kind	Date	Applic	: No	Kind	Date		
ΑU	9928767	<b>A</b> 1	20000914	AU	99287	67	Α	19990225	
UΑ	200020591	A5	20000801	AU	59205	91	Α	19991223	
AU	200077021	A5	20010417	AU	20007	7021	Α	20000914	
AU	200127834	A5	20010724	AU	20012	7834	Α	20010112	
BR	9916881	Α	20020507	BR	99U16	881	Α	19991223	
BR	9917152	Α	20021126	BR	99U17	152	Α	19990225	
BR	200013998	A	20020514	BR	20001	3998	Α	20000914	
CA	2359109	AA	20000720	CA	23591	.09	Α	19991223	
CA	2366712	AA	20000831	CA	23667	12	Α	19990225	
CA	2384881	AA	20010322	CA	23848	81	Α	20000914	
CA	2397386	AA	20010719	CA	23973	86	Α	20010112	
CN	1337878	T	20020227	CN	99816	287	Α	19991223	
CN	1390135	T	20030108	CN	20008	15660	Α	20000914	
CN	1418108	$\mathbf{T}$	20030514	CN	20018	06307	Α	20010112	
EP	1140028	A1	20011010	EP	99964	321	Α	19991223	
EP	1162994	A1	20011219	EP	99909	595	Α	19990225	
EP	1212080	A2	20020612	EP	20009	66719	Α	20000914	
ΕP	1246641	A2	20021009	EP	20019	01984	Α	20010112	
HU	200202670	AB	20021128	HU	20022	670	Α	19991223	
HU	200203523	AB	20030228	HU	20023	523	A	20000914	
$_{ m IL}$	144087	A0	20020523	$_{ m IL}$	14408	7	Α	19991223	
$_{ m IL}$	145087	A0	20020630	$_{ m IL}$	14508	7	Α	19990225	
$_{ m IL}$	148651	A0	20020912	$_{ t IL}$	14865	1	Α	20000914	
IL	150675	A0	20030212	$_{ m IL}$	15067	5	Α	20010112	
JP	2002537350	A2	20021105	JP	20006	00679	Α	19990225	
JP	2002534456	T2	20021015	JP	20005	93290	Α	19991223	
JP	2003509375	T2	20030311	JP	20015	23017	. A	20000914	
JP	2003519665	T2	20030624	JP	20015	51496	Α	20010112	
NO	200103402	Α	20010911	NO	20013	402	Α	20010709	
NO	200103402	A0	20010709	· NO	20013	402	Α	20010709	
NZ	514260	Α	20030228	NZ	51426	0	Α	19990225	
PL	352876	A1	20030922	PL	35287	6	Α	19990225	
PL	354259	<b>A</b> 1	20031229	$_{ m PL}$	35425	9	Α	20000914	
TR	200102012	T2	20020121	TR	20010	2012	A	19991223	
TR	200201484	T2	20030221	TR	20020	1484	Α	20000914	
US	5985271	Α	19991116	US	25702	6	Α	19990225	(BASIC)
US	5997862	Α	19991207	US	96252	:3	Α	19971031	
US	6017528	Α	20000125	US	25702	:5	Α	19990225	
US	6056954	Α	20000502	US	39563	6	Α	19990914	
US	2001003884	9 AA	20011108	US	81937	6	Α	20010328	
US	2002002205	1 AA	20020221	US	93246	0	Α	20010820	
	2002008126		20020627	US	83142		Α	20020227	
US	2002009036	7 AA	20020711	US	67979	)	Α	20020208	

US	20020094319	AA	20020718	US	12032	Α	20011211
US	20020094330	AA	20020718		67991	Α	20020208
US	20020098234	AA	20020725	US	83462	Α	20020227
US	20020119131	AA	20020829	US	67995	Α	20020208
US	20020119132	AA	20020829	US	104488	Α	20020325
US	20020119133	AA	20020829	US	105075	Α	20020325
US	20020119134	AA	20020829	US	105076	A	20020325
US	20020127206	AA	20020912	US	908737	Α	20010719
US	20020127212	AA	20020912	US		Α	20010525
US	20020127212	AA	20020912	US	752731	Α	20010103
US	20020127213	AA	20020912	US	145604	A	20020514
US	20020127220	AA	20020912	US	960472	A	20020314
	20020136712	AA	20020928	US	135851	A	20010521
US			20021010	US	135824	Ā	20020501
US	20020146403	AA AA	20021010	US	135825	A	20020501
US	20020159987				135825	A	20020501
US	20020159988	AA	20021031	US		A	20020501
US	20030082110	AA	20030501	US	176375		
US	20030113298	AA	20030619		846688	A	20010502 20020816
US	20030129146	AA	20030710	US	219250	A	
US	20030129147	AA	20030710	US	219251	A	20020816
US	20030138493	AA	20030724	US		A	20021004
US	20040071774	AA	20040415		641301	A	20030814
US		AA	20040422	US	720266	Α	20031125
US	20040076624	AA	20040422		465889	Α	20030620
US		BA	20010529		497495	A	20000418
US	6248324	BA	20010619		671879	Α	20000928
US		BA	20010703	US	653690	Α	20000901
	6264945	BA	20010724	US	482992	Α	20000114
US		BA	20010821	US		Α	20000928
US	6326002	BA	20011204	US		Α	20000928
US		BA	20020101	US		Α	20000928
US	6350464	BA	20020226	US	227852	Α	19990111
US	6399097	BA	20020604	US	654482	Α	20000901
US	6399098	BA	20020604	US	671991	Α	20000928
US	6406692	BA	20020618	US	671880	Α	20000928
US	6423299	BA	20020723	US	654483	Α	20000901
US	6428784	BA	20020806	US	671881	Α	20000928
US	6432444	BA	20020813	US	671878	A	20000928
US	6479067	BB	20021112	US	819376	Α	20010328
US	6641833	BB	20031104	US	264793	Α	20021004
US	6685937	BB	20040203	US	866106	Α	20010525
WO	200041678	A1	20000720	WO	99US30814	Α	19991223
WO	200050069	A1	20000831	WO	99US4063	Α	19990225
	200119385	A2	20010322	WO	2000US25093	Α	20000914
	200151073	A2	20010719	WO	2001US913	Α	20010112
	200324410	A2	20030327	WO	2002US30099	Α	20020923
WO	200400222	A2	20031231		2003US19654	Α	20030623
	200119385	A3	20011122		2000US25093	A	20000914
	200151073	A3	20011220		2001US913	A	20010112
	200119385	C2	20020926		2000US25093	Α	20000914
	200151073	C2	20020808		2001US913	Α	20010112
	200106499	A	20021107		20016499	A	20010807
	200202305	A	20020930		20022305	A	20020322
	20012416	A3	20011114		20012416	A	19991223
	ty Data (No,K				20012110	••	1,,,,1000
	-	1999					
		9902			•		
		9901					
	99US30814 W		91223				
		9909					
	2000US25093		0000914				
		0001					
		0101					
	2001IIS913 W						

WO 2001US913 W 20010112 WO 99US4063 W 19990225 NZ 514260 A 19990225 PL 352876 A 19990225 US 257026 A 19990225 US 962523 A3 19971031

US 962523 A 19971031 US 962523 A2 19971031 US 962523 A1 19971031 US 819376 A 20010328 US 227852 A1 19990111 US 932460 A 20010820 US 671882 A1 20000928 US 497495 A2 20000418 US 395636 A1 19990914 US 83142 A 20020227 US 654483 A1 20000901 US 67979 A 20020208 US 671880 A1 20000928 US 12032 A 20011211 US 671992 A1 20000928 US 67991 A 20020208 US 83462 A 20020227 US 654482 A1 20000901 US 67995 A 20020208 US 104488 A 20020325 US 671881 A1 20000928 US 105075 A 20020325 US 105076 A 20020325 20010719 US 908737 A US 482992 A1 20000114 US 395636 A2 19990914 US 866106 A 20010525 US 497495 A1 20000418 US 482992 A2 20000114 US 145604 A 20020514 US 960472 A 20010921 US 846688 A2 20010502 US 135851 A 20020501 US 135824 A 20020501 US 135825 A 20020501 20020501 US 135826 A US 671878 A1 20000928 US 176375 A 20020621 US 671881 A2 20000928 US 846688 A 20010502 US 219250 A 20020816 US 219251 A 20020816 US 264793 A 20021004 US 819376 A1 20010328 US 641301 A 20030814 US 264793 A1 20021004 US 720266 A 20031125 US 83142 A1 20020227 US 465889 A 20030620 US 932460 A1 20010820 US 497495 A 20000418 US 671879 A 20000928 US 395636 A1 20000914 US 653690 A 20000901 US 671882 A 20000928 US 671990 A 20000928 US 671992 A 20000928 US 654482 A 20000901 US 671991 A 20000928 US 671880 A 20000928 US 654483 A 20000901 US 671881 A 20000928 US 671878 A 20000928 US 324089 P 20010924 US 176405 A 20020621

Dialog File: Inpadoc/Fam.& Legal Stat 1968-2004/UD=200419

```
(Item 1 from file: 357)
 2/3,KWIC/75
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2004 Thomson Derwent & ISI. All rts. reserv.
0305070 DBR Accession No.: 2003-06855
                                         PATENT
Novel genetically labeled bacteriophage for use in prophylactic and
    therapeutic treatment of bacterial infections in plants, livestock,
   birds and humans, and for environmental clean up and sanitation -
    genetically labeled phage production and detcetion for bacterium
    infection
AUTHOR: MANDEVILLE R; ALLAIN B; MURTHY K
PATENT ASSIGNEE: BIOPHAGE INC 2002
PATENT NUMBER: WO 200286154 PATENT DATE: 20021031 WPI ACCESSION NO.:
    2003-058729 (200305)
PRIORITY APPLIC. NO.: US 284517 APPLIC. DATE: 20010419
NATIONAL APPLIC. NO.: WO 2002CA569 APPLIC. DATE: 20020419
LANGUAGE: English
Novel genetically labeled bacteriophage for use in prophylactic and
    therapeutic treatment of bacterial infections in plants, livestock,
    birds and humans, and for environmental clean up...
?logoff hold
       26may04 08:30:49 User228206 Session D2178.4
                  0.245 DialUnits File155
            $0.79
               $2.31 11 Type(s) in Format 9
            $2.31 11 Types
           Estimated cost File155
     $3.10
            $0.31
                   0.032 DialUnits File73
               $5.40 2 Type(s) in Format 9
            $5.40 2 Types
           Estimated cost File73
     $5.71
            $0.06
                    0.011 DialUnits File286
     $0.06 Estimated cost File286
            $0.23
                    0.011 DialUnits File440
     $0.23 Estimated cost File440
                    0.011 DialUnits File340
            $0.17
           Estimated cost File340
     $0.17
            $0.22
                    0.011 DialUnits File434
     $0.22 Estimated cost File434
            $0.06
                    0.011 DialUnits File5
     $0.06 Estimated cost File5
                    0.053 DialUnits File399
               $5.50 2 Type(s) in Format 3
            $5.50 2 Types
     $6.17
           Estimated cost File399
                    0.011 DialUnits File144
            $0.04
     $0.04 Estimated cost File144
                    0.011 DialUnits File348
            $0.05
     $0.05 Estimated cost File348
                   0.011 DialUnits File9
            $0.06
     $0.06 Estimated cost File9
                    0.011 DialUnits File34
            $0.22
     $0.22 Estimated cost File34
                   0.011 DialUnits File128
            $0.32
     $0.32 Estimated cost File128
                     0.011 DialUnits File319
            $0.06
     $0.06 Estimated cost File319
                     0.011 DialUnits File342
            $0.18
     $0.18 Estimated cost File342
            $0.05
                     0.011 DialUnits File349
     $0.05 Estimated cost File349
                     0.032 DialUnits File50
            $0.14
               $2.00 1 Type(s) in Format 9
            $2.00 1 Types
     $2.14 Estimated cost File50
            $0.12
                     0.011 DialUnits File107
     $0.12 Estimated cost File107
```

0.096 DialUnits File345

\$10.55 1 Type(s) in Format 3

\$0.46

```
$10.55 1 Types
$11.01 Estimated cost File345
               0.043 DialUnits File357
       $0.83
          $2.27 1 Type(s) in Format 3
       $2.27 1 Types
       Estimated cost File357
$3.10
                0.011 DialUnits File16
       $0.06
       Estimated cost File16
$0.06
                0.011 DialUnits File35
$0.04
       Estimated cost File35
                0.011 DialUnits File71
       $0.08
$0.08 Estimated cost File71
                0.011 DialUnits File98
       $0.03
 $0.03 Estimated cost File98
                0.011 DialUnits File143
       Estimated cost File143
 $0.03
       OneSearch, 25 files, 0.704 DialUnits FileOS
$0.24
       TELNET
$33.55 Estimated cost this search
$33.55 Estimated total session cost 0.704 DialUnits
```

### Status: Signed Off. (1 minutes)

01524737

- METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES
- PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES
  THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET
  PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES
  PATENT ASSIGNEE:
- Biophage, Inc., (3936210), 6100 Royalmount, Montreal, Quebec H4P 2R2, (CA), (Applicant designated States: all)
  INVENTOR:
- MANDEVILLE, Rosemonde, 781 Thibault, Ste-Therese, Quebec J7E 4B9, (CA) ALLAIN, Beatrice, 8434 St-Hubert, Montreal, Quebec H2P 1Z5, (CA) MURTHY, Kishore, 24 Linton, Dollard des Ormeaux, Quebec H9B 1P3, (CA) PATENT (CC, No, Kind, Date):
- WO 2002086154 021031

  APPLICATION (CC, No, Date): EP 2002764031 020419; WO 2002CA569 020419

  PRIORITY (CC, No, Date): US 284517 P 010419

  DESIGNATED STATES: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE; TR

  EXTENDED DESIGNATED STATES: AL; LT; LV; MK; RO; SI

  INTERNATIONAL PATENT CLASS: C12Q-001/68

  LANGUAGE (Publication, Procedural, Application): English; English
- METHODS FOR GENERATING LIBRARIES OF THERAPEUTIC BACTERIOPHAGES HAVING DESIRED SAFETY CHARACTERISTICS AND METHODS FOR LABELING AND MONITORING BACTERIOPHAGES
- PROCEDES PERMETTANT DE PRODUIRE DES BIBLIOTHEQUES DE BACTERIOPHAGES
  THERAPEUTIQUES POSSEDANT DES CARACTERISTIQUES DE SECURITE DESIREES ET
  PROCEDES DE MARQUAGE ET DE SURVEILLANCE DESDITS BACTERIOPHAGES
  ?logoff hold

## First Hit Fwd Refs

Generate Collection

L7: Entry 42 of 63

File: USPT

Nov 18, 1997

DOCUMENT-IDENTIFIER: US 5688501 A

TITLE: Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system

## Brief Summary Text (26):

Enabling bacteriophages to delay inactivation by those host defense systems--whichever components of it may or may not be employed in any given case--would be likely to result in an increased in vivo killing of bacterial pathogens that are in the host range for those bacteriophages.

#### CLAIMS:

1. A <u>method for treating</u> an infectious disease caused by bacteria in an animal comprising:

administering to an animal in need of such treatment lytic or non-lytic bacteriophages that are specific for said bacteria in a dosage effective to substantially eliminate the bacteria, wherein said bacteriophages are obtained by serial passage through an animal's circulatory system of mutagenized or non-mutagenized bacteriophages and are selected to have at least a 15% longer half-life in the animal's circulatory system than corresponding wild-type bacteriophages, wherein said at-least 15% longer half-life is genetically inheritable and wherein said bacteriophages having at least 15% longer half-life contact said bacteria during the course of the infectious disease.

- 2. The  $\underline{\text{method}}$  according to claim 1, wherein said bacteria are drug resistant bacteria.
- 3. The method according to claim 1, wherein said animal is not a mammal.
- 4. The method according to claim 1, wherein said animal is a mammal.
- 5. The  $\underline{\text{method}}$  according to claim 1, wherein the  $\underline{\text{bacteriophages are administered}}$  by way of an aerosol to an animal's lungs.
- 6. The  $\underline{\text{method}}$  according to claim 1, wherein the  $\underline{\text{bacteriophages are administered}}$  at a a dosage of about 10.sup.6 to about 10.sup.13 pfu/kg/day.
- 7. The  $\underline{\text{method}}$  according to claim 6, wherein the  $\underline{\text{bacteriophages}}$  are administered at a dosage of about 10.sup.12 pfu/kg/day.
- 8. The method according to claim 1, wherein said infectious disease is systemic.
- 9. The <u>method</u> according to claim 1, wherein the bacteria belong to a genus selected from the group consisting of Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococcus, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella, Streptococcus, Klebsiella and Yersinia, and wherein the <u>bacteriophages</u> can effectively lyse the bacteria.
- 10. The method according to claim 9, wherein the bacteria belong to the genus

# ATCC cultures."

Search:	Choose Option	V
	The suppose of the su	,

| Home | Ordering Info | Quick Order | Cart | Tech Support | Contact Us

# Make a Deposit

#### ATCC Cultures

Bacteria
Bacteriophages
Cell Lines & Hybridomas
Filamentous Fungi &
Yeast
Plant Tissue Cultures
Plant Seeds
Protozoa & Algae
Viruses & Antisera
Animal
Plant

## ATCC Bioproducts

Molecular Genomics Cell Biology Microbiology

#### ATCC Special Collections 🐲

Johns Hopkins University National Park Service Wistar Institute Yeast Genetic Research Resource Center

## ATCC Services

Patent Depository Culture Safe Deposit Mycoplasma Testing

## About ATCC

Mission
Announcements
BEI Resources
Malaria Resource Center
National Stem Cell
Resource
Career Information
Site Map
Contact Us

## **Bacteriophages**

## **Search Bacteriophages Collection Catalog**

| Advanced field search | Search Bacteria | Search Help |

Enter ATCC Number:	AND THE RESIDENCE OF THE PROPERTY OF THE PROPE
OR	Submit Search Clear Search
Query database:	streptococcus
	Display 20 entries on each screen
	Submit Search Clear Search

The ATCC Bacteriology Collection is the most diversified assemblage of prokaryotes in the containing nearly 18,000 strains in more than 750 genera. Every important prokaryotic p group is represented. The Collection holds more than 3,600 type cultures of validly descriforming the basis for systematic bacteriology, and nearly 500 bacteriophages. The Bacter catalog is divided into two subcollections. Please choose the appropriate one to find the s need.

- Bacteriophages advanced field search
- Search Bacteria Collection Catalog
- Make a Deposit
- Frequently Asked Questions (FAQ)
- Material Transfer Agreement
- Technical Services
- Genomic DNA from bacteria
- Preceptrol Strains

The bacteria are useful in a variety of research and industrial applications. We have <u>quality</u> organisms for commercial identification systems and a wide selection of <u>extremophile strains</u> variety of environmental sources. (You can view these lists of specialized strains using <u>Ac Reader</u>.)

#### **New Bacteria**

- 49467D Acinetobacter sp. genomic DNA from Acinetobacter sp.
- 7965D Aeromonas hydrophila genomic DNA from Aeromonas hydrophila
- BAA-456 Butyrivibrio hungatei JK 615

Mycobacteria and are selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium avium-intracellulare and Mycobacterium bovis.

- 11. The <u>method</u> according to claim 1, wherein said <u>bacteriophages</u> having at least 15% longer half-life contact said bacteria via the animal's circulatory system.
- 12. Isolated and purified <u>bacteriophages</u> that have been obtained by serial passage of mutagenized or non-mutagenized <u>bacteriophages</u> through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type <u>bacteriophages</u>, wherein said atleast 15% longer half-life is genetically inheritable.
- 13. The <u>bacteriophages</u> of claim 12, wherein said <u>bacteriophages</u> are specific for a bacterial genus selected from the group consisting of Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococcus, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella, Streptococcus, Klebsiella and Yersinia.
- 14. A pharmaceutical composition comprising isolated and purified <u>bacteriophages</u> that have been obtained by serial passage of mutagenized or non-mutagenized <u>bacteriophages</u> through an animal's circulatory system and selected to have at least a 15% longer half-life in said animal's circulatory system than corresponding wild-type <u>bacteriophages</u>, wherein said at-least 15% longer half-life is genetically inheritable, in combination with a pharmaceutically acceptable carrier.
- 16. The pharmaceutical composition according to claim 14, wherein said bacteriophage is in lyophilized form.